Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Relationship Between Patient Satisfaction and the Degree of Valgus Deformity in Lateral Unicompartmental Knee Arthroplasty at a Mean 3-Year Follow-Up.

The Journal of arthroplasty·2026
Same author

A multicenter randomized controlled trial and metabolomics exploration of Traditional Chinese Medicine pattern-based therapy for stable chronic obstructive pulmonary disease.

Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan·2026
Same author

Highly Emissive Double π-Helical Molecular Carbons via Nitrogen Integration.

Angewandte Chemie (International ed. in English)·2026
Same author

N-Bordered Rylene Arches via Programmable Curved π-Extension.

Nature communications·2026
Same author

Effect of repetition tempo on cardiovascular and metabolic stress when training to muscle failure during lower body exercise.

European journal of applied physiology·2026
Same author

Correction to: Improving aptamer binding affinity for HN protein of newcastle disease virus: molecular dynamics simulations and MM/GBSA calculations studies.

Molecular diversity·2026
Same journal

The risk of retinal vascular events in patients using semaglutide: a scoping review.

Ophthalmologica. Journal international d'ophtalmologie. International journal of ophthalmology. Zeitschrift fur Augenheilkunde·2026
Same journal

Interpreting relative afferent pupillary defect in Leber hereditary optic neuropathy using interocular visual acuity difference.

Ophthalmologica. Journal international d'ophtalmologie. International journal of ophthalmology. Zeitschrift fur Augenheilkunde·2026
Same journal

1 MONTH VS. 3 MONTHS HEAVY SILICONE OIL TAMPONADE IN COMPLEX RHEGMATOGENOUS RETINAL REDETACHMENT.

Ophthalmologica. Journal international d'ophtalmologie. International journal of ophthalmology. Zeitschrift fur Augenheilkunde·2026
Same journal

Visual loss after silicone oil removal - Analysis of a German cohort.

Ophthalmologica. Journal international d'ophtalmologie. International journal of ophthalmology. Zeitschrift fur Augenheilkunde·2026
Same journal

Weekend effect on vitrectomy: Insights from a Nationwide Population-Based Study in Korea.

Ophthalmologica. Journal international d'ophtalmologie. International journal of ophthalmology. Zeitschrift fur Augenheilkunde·2026
Same journal

The Royal College of Ophthalmologists National Ophthalmology Database Age-related Macular Degeneration (AMD) Audit, Report 2: Baseline characteristics, the care pathway and 12-month visual acuity and safety outcomes for 54,882 eyes starting treatment for neovascular AMD.

Ophthalmologica. Journal international d'ophtalmologie. International journal of ophthalmology. Zeitschrift fur Augenheilkunde·2026
See all related articles

Related Experiment Video

Updated: Dec 25, 2025

Encapsulated Cell Technology for the Delivery of Biologics to the Mouse Eye
06:10

Encapsulated Cell Technology for the Delivery of Biologics to the Mouse Eye

Published on: March 30, 2020

8.2K

Current choroidal neovascularization treatment.

Liu Jian1, Ye Panpan, Xu Wen

  • 1Eye Center, Second Affiliated Hospital, School of Medicine, Zhejiang University, Zhejiang Provincial Key Laboratory of Ophthalmology, Hangzhou, PR China.

Ophthalmologica. Journal International D'Ophtalmologie. International Journal of Ophthalmology. Zeitschrift Fur Augenheilkunde
|August 17, 2013
PubMed
Summary
This summary is machine-generated.

Anti-vascular endothelial growth factor (VEGF) therapy is now the primary treatment for choroidal neovascularization (CNV), offering improved vision and toleration. Ongoing research explores new strategies to extend treatment intervals and provide alternative options.

More Related Videos

Regenerative Therapy by Suprachoroidal Cell Autograft in Dry Age-related Macular Degeneration: Preliminary In Vivo Report
10:24

Regenerative Therapy by Suprachoroidal Cell Autograft in Dry Age-related Macular Degeneration: Preliminary In Vivo Report

Published on: February 12, 2018

10.6K
In Vivo Multimodal Imaging and Analysis of Mouse Laser-Induced Choroidal Neovascularization Model
09:56

In Vivo Multimodal Imaging and Analysis of Mouse Laser-Induced Choroidal Neovascularization Model

Published on: January 21, 2018

9.7K

Related Experiment Videos

Last Updated: Dec 25, 2025

Encapsulated Cell Technology for the Delivery of Biologics to the Mouse Eye
06:10

Encapsulated Cell Technology for the Delivery of Biologics to the Mouse Eye

Published on: March 30, 2020

8.2K
Regenerative Therapy by Suprachoroidal Cell Autograft in Dry Age-related Macular Degeneration: Preliminary In Vivo Report
10:24

Regenerative Therapy by Suprachoroidal Cell Autograft in Dry Age-related Macular Degeneration: Preliminary In Vivo Report

Published on: February 12, 2018

10.6K
In Vivo Multimodal Imaging and Analysis of Mouse Laser-Induced Choroidal Neovascularization Model
09:56

In Vivo Multimodal Imaging and Analysis of Mouse Laser-Induced Choroidal Neovascularization Model

Published on: January 21, 2018

9.7K

Area of Science:

  • Ophthalmology
  • Retinal Diseases
  • Medical Treatments

Background:

  • Choroidal neovascularization (CNV) is a significant cause of vision loss.
  • Treatment has evolved from laser photocoagulation and photodynamic therapy.
  • Anti-vascular endothelial growth factor (VEGF) therapy represents a major advancement.

Purpose of the Study:

  • To review the current landscape of choroidal neovascularization (CNV) treatments.
  • To highlight the evolution of CNV management strategies.
  • To discuss emerging therapeutic approaches for CNV.

Main Methods:

  • Literature search of MEDLINE (2001-2013) for CNV therapy studies.
  • Inclusion of original research (phase I, II, III), abstracts, and reviews.
  • Inclusion of relevant information from associated websites.

Main Results:

  • Anti-VEGF therapy has become the standard of care for CNV.
  • Patients experience enhanced visual acuity and better toleration with anti-VEGF treatments.
  • Combination therapies show potential for reduced retreatment frequency and sustained benefits.
  • Exploration of anti-inflammatory and further anti-VEGF agents is ongoing.

Conclusions:

  • Anti-VEGF monotherapy is the current first-line treatment for CNV.
  • Further research aims to prolong treatment intervals and offer alternative therapeutic options for CNV patients.